Prevalence and Associated Factors of SARS by Covid-19 in Adults and Aged People with Chronic Cardiovascular Disease
Overview
Authors
Affiliations
Background: The presence of Cardiovascular Disease (CVD) in individuals infected with COVID-19 may imply a worse prognosis.
Objective: To describe the prevalence of Severe Acute Respiratory Syndrome (SARS) by COVID-19 and to analyze the factors associated with this condition in adults and the elderly with cardiovascular disease in Brazil until the 30th Epidemiological Week of 2020.
Methods: Cross-sectional study conducted with data from the Influenza Epidemiological Surveillance Information System (Sistema de Informação de Vigilância Epidemiológica da Gripe - SIVEP-Gripe), referring to the SARS notification forms of hospitalized individuals in Brazil, between the 1st and 30th Epidemiological Week of 2020. Adults and the aged (≥ 18 years old) with CVD. The dependent variable was SRAG confirmation by COVID-19 and factors related to sociodemographic characteristics, signs and symptoms, and clinical factors were analyzed. Poisson regression with robust variance was applied. The level of significance adopted was 5%.
Results: Notifications from 116,343 individuals were analyzed. Of these, 61.9% were diagnosed with SARS by COVID-19. The prevalence of the outcome was 4% lower in women (95%CI: 0.94-0.99) and 18% lower in rural areas (95%CI: 0.77-0.87). There was a higher prevalence in the 50 to 59 age group (95%CI: 1.09-1.48) and in the northeast region (95%CI: 1.72-1.91). Fever, cough, admission to the ICU, use of ventilatory support, and nosocomial cases were also significantly associated with a higher probability of SRAS by COVID-19 in these individuals.
Conclusion: There is a high prevalence of SARS by COVID-19 in adults and aged people with CVD in Brazil. Factors associated with sociodemographic and clinical characteristics, signs, and symptoms were associated.
Salci M, Carreira L, Oliveira N, Pereira N, Covre E, Pesce G Healthcare (Basel). 2024; 12(14).
PMID: 39057586 PMC: 11276565. DOI: 10.3390/healthcare12141443.
ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose.
Santos A, Francisco Q, Nunes J, Colombo F, Boralli V Braz J Med Biol Res. 2024; 57:e13257.
PMID: 38958362 PMC: 11221861. DOI: 10.1590/1414-431X2024e13257.
Rhoden J, Hoffmann A, Stein J, da Rocha B, Monteagudo de Barros V, Viegas da Silva E Respir Res. 2024; 25(1):71.
PMID: 38317218 PMC: 10840208. DOI: 10.1186/s12931-024-02708-2.
Novaes T, Lara D, da Silva S J Racial Ethn Health Disparities. 2023; 11(4):1908-1917.
PMID: 37314690 DOI: 10.1007/s40615-023-01660-z.
Lucchetta R, Matuoka J, de Oliveira Junior H, Oliveira G, Biasi Cavalcanti A, Azevedo L Arq Bras Cardiol. 2023; 120(4):e20220380.
PMID: 37042856 PMC: 10263429. DOI: 10.36660/abc.20220380.